Dramatic decreases in HIV transmission are achievable with currently available biomedical and behavioral interventions, including antiretroviral therapy and pre-exposure prophylaxis. However, such decreases have not yet been realized among adolescents and young adults. The Adolescent Medicine Trials Network (ATN) for HIV/AIDS interventions is dedicated to research addressing the needs of youth at high risk for HIV acquisition as well as youth living with HIV. This article provides an overview of an array of efficient and effective designs across the translational spectrum that are utilized within the ATN. These designs maximize methodological rigor and real-world applicability of findings while minimizing resource use. Implementation science and cost-effectiveness methods are included. Utilizing protocol examples, we demonstrate the feasibility of such designs to balance rigor and relevance to shorten the science-to-practice gap and improve the youth HIV prevention and care continua.

Get full access to this article

View all available purchase options and get full access to this article.


1. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375:830–839.
2. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016;30:1973–1983.
3. Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: Exaggerated health disparities. AIDS Patient Care STDS 2014;28:128–135.
4. Parsons JT, Rendina HJ, Lassiter JM, Whitfield TH, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States. J Acquir Immune Defic Syndr 2017;74:285–292.
5. Freese TE, Padwa H, Oeser BT, Rutkowski BA, Schulte MT. Real-world strategies to engage and retain racial-ethnic minority young men who have sex with men in HIV prevention services. AIDS Patient Care STDS 2017;31:275–281.
6. Mullins TLK, Zimet G, Lally M, Xu J, Thornton S, Kahn JA. HIV care providers' intentions to prescribe and actual prescription of pre-exposure prophylaxis to at-risk adolescents and adults. AIDS Patient Care STDS 2017;31:504–516.
7. Grieb SM, Reddy M, Griffin B, et al. Identifying solutions to improve the sexually transmitted infections testing experience for youth through participatory ideation. AIDS Patient Care STDS 2018;32:330–335.
8. Elopre L, McDavid C, Brown A, Shurbaji S, Mugavero MJ, Turan JM. Perceptions of HIV pre-exposure prophylaxis among young, black men who have sex with men. AIDS Patient Care STDS 2018;32:511–518.
9. MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav 2013;17:86–93.
10. MacDonell KK, Jacques-Tiura AJ, Naar S, Fernandez MI ATN 086/106 Protocol Team. Predictors of self-reported adherence to antiretroviral medication in a multisite study of ethnic and racial minority HIV-positive youth. J Pediatr Psychol 2016;41:419–428.
11. Rubio DM, Schoenbaum EE, Lee LS, et al. Defining translational research: Implications for training. Acad Med 2010;85:470–475.
12. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard—lessons from the history of RCTs. N Engl J Med 2016;374:2175–2181.
13. Chattu V. Role of biomedical and behavioral interventions and their evidence in prevention of HIV infection: A literature review. Int J Med Sci Public Health 2014;4:324–330.
14. Lambdin BH, Cheng B, Peter T, et al. Implementing implementation science: An approach for HIV prevention, care and treatment programs. Curr HIV Res 2015;13:244–249.
15. Czajkowski SM, Powell LH, Adler N, et al. From ideas to efficacy: The ORBIT model for developing behavioral treatments for chronic diseases. Health Psychol 2015;34:971–982.
16. Bacon SL, Lavoie KL, Ninot G, et al. An international perspective on improving the quality and potential of behavioral clinical trials. Curr Cardiovas Risk Rep 2015;9:427.
17. Rosbash M. A threat to medical innovation. Science 2011;333:136.
18. Yardley L, Morrison L, Bradbury K, Muller I. The person-based approach to intervention development: Application to digital health-related behavior change interventions. J Med Internet Res 2015;17:e30.
19. Naar-King S, Suarez M. Motivational Interviewing with Adolescents and Young Adults. New York: Guilford Press; 2011.
20. Vergani S. Using Human-Centered Design to Develop Behavioral Interventions. Workshop on Innovative Study Designs and Methods for Developing, Testing, and Implementing Behavioral Interventions to Improve Health. Bethesda, MD: National Institutes of Health, 2014.
21. Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice-Hall, Inc., 1986.
22. Bandura A. Social cognitive theory. Handbook of Theories of Social Psychology: Volume 2, 2012. London: Sage.
23. Fogg BJ. Persuasive technology: Using computers to change what we think and do. Ubiquity 2002;2002:5.
24. Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based practice implementation in public service sectors. Adm Policy Ment Health 2011;38:4–23.
25. Franx G, Oud M, de Lange J, Wensing M, Grol R. Implementing a stepped-care approach in primary care: Results of a qualitative study. Implement Sci 2012;7:8.
26. Gureje O, Oladeji BD, Araya R, Montgomery AA. A cluster randomized clinical trial of a stepped care intervention for depression in primary care (STEPCARE)—study protocol. BMC Psychiatry 2015;15:148.
27. Murphy SA. Optimal dynamic treatment regimes. J R Stat Soc Series B Stat Methodol 2003;65:331–355.
28. Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA. Introduction to SMART designs for the development of adaptive interventions: With application to weight loss research. Transl Behav Med 2014;4:260–274.
29. Naar-King S, Ellis DA, Carcone AI, et al. Sequential Multiple Assignment Randomized Trial (SMART) to construct weight loss interventions for African American adolescents. J Clin Child Adolesc Psychol 2016;45:428–441.
30. Torgerson DJ. Contamination in trials: Is cluster randomisation the answer? BMJ 2001;322:355–357.
31. Donner A, Klar N. Pitfalls of and controversies in cluster randomization trials. Am J Public Health 2004;94:416–422.
32. Spiegelhalter DJ. Bayesian methods for cluster randomized trials with continuous responses. Stat Med 2001;20:435–452.
33. Turner RM, Omar RZ, Thompson SG. Bayesian methods of analysis for cluster randomized trials with binary outcome data. Stat Med 2001;20:453–472.
34. Clark AB, Bachmann MO. Bayesian methods of analysis for cluster randomized trials with count outcome data. Stat Med 2010;29:199–209.
35. Singh SP, Mukhopadhyay S, Roy A. Comparison of three-level cluster randomized trials using quantile dispersion graphs. J Appl Stat 2015;42:1792–1812.
36. Heo M, Leon AC. Statistical power and sample size requirements for three level hierarchical cluster randomized trials. Biometrics 2008;64:1256–1262.
37. Fazzari MJ, Kim MY, Heo M. Sample size determination for three-level randomized clinical trials with randomization at the first or second level. J Biopharm Stat 2014;24:579–599.
38. Heo M, Litwin AH, Blackstock O, Kim N, Arnsten JH. Sample size determinations for group-based randomized clinical trials with different levels of data hierarchy between experimental and control arms. Stat Methods Med Res 2017;26:399–413.
39. Moerbeek M, Gerard JPvB, Martijn PFB. Design issues for experiments in multilevel populations. J Educ Behav Stat 2000;25:271–284.
40. Heo M, Leon AC. Sample size requirements to detect an intervention by time interaction in longitudinal cluster randomized clinical trials. Stat Med 2009;28:1017–1027.
41. Heo M, Xue X, Kim MY. Sample size requirements to detect an intervention by time interaction in longitudinal cluster randomized clinical trials with random slopes. Comput Stat Data Anal 2013;60:169–178.
42. Flynn TN, Whitley E, Peters TJ. Recruitment strategies in a cluster randomized trial—cost implications. Stat Med 2002;21:397–405.
43. Campbell MJ, Donner A, Klar N. Developments in cluster randomized trials and statistics in medicine. Stat Med 2007;26:2–19.
44. Klar N, Donner A. Current and future challenges in the design and analysis of cluster randomization trials. Stat Med 2001;20:3729–3740.
45. Kenny DA, Kashy DA, Cook WL. Dyadic Data Analysis. New York: Guilford Press, 2006.
46. Mustanski B, Starks T, Newcomb ME. Methods for the design and analysis of relationship and partner effects on sexual health. Arch Sex Behav 2014;43:21–33.
47. Sullivan PS, White D, Rosenberg ES, et al. Safety and acceptability of couples HIV testing and counseling for US men who have sex with men: A randomized prevention study. J Int Assoc Provid AIDS Care 2014;13:135–144.
48. Stephenson R, Sullivan PS, Salazar LF, Gratzer B, Allen S, Seelbach E. Attitudes towards couples-based HIV testing among MSM in three US cities. AIDS Behav 2011;15 Suppl 1:S80–S87.
49. Kenny DA, Kashy DA, Cook WL, Simpson J. Dyadic Data Analysis (Methodology in the Social Sciences). New York: Guilford, 2006.
50. Brown CH, Wyman PA, Guo J, Pena J. Dynamic wait-listed designs for randomized trials: New designs for prevention of youth suicide. Clin Trials 2006;3:259–271.
51. Wyman PA, Henry D, Knoblauch S, Brown CH. Designs for testing group-based interventions with limited numbers of social units: The dynamic wait-listed and regression point displacement designs. Prev Sci 2015;16:956–966.
52. Brown CA, Lilford RJ. The stepped wedge trial design: A systematic review. BMC Med Res Methodol 2006;6:54.
53. Fok CC, Henry D, Allen J. Research designs for intervention research with small samples II: Stepped wedge and interrupted time-series designs. Prev Sci 2015;16:967–977.
54. Brown CH, Curran G, Palinkas LA, et al. An overview of research and evaluation designs for dissemination and implementation. Annu Rev Public Health 2017;38:1–22.
55. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials Commun 2007;28:182–191.
56. Fortenberry JD, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM. Implementation of an integrated approach to the national HIV/AIDS strategy for improving human immunodeficiency virus care for youths. JAMA Pediatr 2017;171:687–693.
57. Ford I, Norrie J. Pragmatic trials. N Engl J Med 2016;375:454–463.
58. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: Designing trials that are fit for purpose. BMJ 2015;350:h2147.
59. Roland M, Torgerson DJ. Understanding controlled trials: What are pragmatic trials? BMJ 1998;316:285.
60. Eapen ZJ, Vavalle JP, Granger CB, Harrington RA, Peterson ED, Califf RM. Rescuing clinical trials in the United States and beyond: A call for action. Am Heart J 2013;165:837–847.
61. van Staa T-P, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: Putting them to the test. BMJ 2012;344:e55.
62. Carroll KM, Rounsaville BJ. Bridging the gap: A hybrid model to link efficacy and effectiveness research in substance abuse treatment. Psychiatr Serv 2003;54:333–339.
63. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: Combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care 2012;50:217–226.
64. Simpson KN. Economic modeling of HIV treatments. Curr Opin HIV AIDS 2010;5:242–248.
65. Simpson KN. Design and assessment of cost-effectiveness studies in AIDS populations. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 4:S28–S32.
66. Kim JJ, Maulsby C, Zulliger R, et al. Cost and threshold analysis of positive charge, a multi-site linkage to HIV care program in the United States. AIDS Behav 2015;19:1735–1741.
67. Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics 2009;27:159–165.
68. Pinkerton SD, Galletly CL. Reducing HIV transmission risk by increasing serostatus disclosure: A mathematical modeling analysis. AIDS Behav 2007;11:698.
69. Centers for Disease Control and Prevention. HIV Cost-Effectiveness. 2017. Available at: https://cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html (Last accessed October 1, 2017).
70. Spring B, Hall KL, Moller AC, Falk-Krzesinski HJ. An emerging science and praxis for research and practice teams. Transl Behav Med 2012 Dec;2:411–414.

Information & Authors


Published In

cover image AIDS Patient Care and STDs
AIDS Patient Care and STDs
Volume 33Issue Number 9September 2019
Pages: 388 - 398
PubMed: 31517525


Published online: 11 September 2019
Published in print: September 2019


Request permissions for this article.




Sylvie Naar, PhD [email protected]
Center for Translational Behavioral Science, Florida State University, Tallahassee, Florida.
Michael G. Hudgens, PhD
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Ron Brookmeyer, PhD
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California.
April Idalski Carcone, PhD
Department of Family Medicine and Public Health Sciences, Wayne State University School of Medicine, Detroit, Michigan.
Jason Chapman, PhD
Oregon Social Learning Center, Eugene, Oregon.
Shrabanti Chowdhury, PhD
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Andrea Ciaranello, MD
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts.
W. Scott Comulada, PhD
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California.
Samiran Ghosh, PhD
Department of Family Medicine and Public Health Sciences, Wayne State University School of Medicine, Detroit, Michigan.
Keith J. Horvath, PhD
Department of Psychology, San Diego State University, San Diego, California.
LaDrea Ingram, PhD
Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.
Sara LeGrand, PhD
Duke Global Health Institute, Duke University, Durham, North Carolina.
Cathy J. Reback, PhD
Friends Research Institute, Los Angeles, California.
Kit Simpson, PhD
Department of Healthcare Leadership and Management, Medical University of South Carolina, Charleston, South Carolina.
Bonita Stanton, MD
Hackensack Meridian School of Medicine, Seton Hall University, Newark, New Jersey.
Tyrel Starks, PhD
Department of Psychology, City University of New York–Hunter College, New York, New York.
Dallas Swendeman, PhD
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California.


Address correspondence to: Sylvie Naar, PhD, Department of Behavioral Sciences and Social Medicine, Florida State University, 1115 West Call Street, Tallahassee, FL 32306-4300 [email protected]

Author Disclosure Statement

No competing financial interests exist.

Metrics & Citations



Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options


View PDF/ePub

Full Text

View Full Text







Copy the content Link

Share on social media

Back to Top